Shots:

• Tezspire was approved by the US FDA on Dec 17, 2021 for the add-on maintenance to treat severe asthma in adult and pediatric patients (aged 12 yrs and older) and is now available for shipment to wholesalers in the US
• Tezspire demonstrated reduced asthma attacks across P-II and III clinical trials including a broad population of severe asthma patients irrespective of key biomarkers which are blood eosinophil counts, allergic status and fractional exhaled FeNO
• Additionally, Tezspire is in development for other indications including chronic obstructive pulmonary disease, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria and EoE. Tezepelumab has received ODD by the US FDA for the treatment of EoE in Oct 2021

Ref: PR Newswire | Image: Fierce Pharma